Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Melicica has potential applications in skin repair, scar and acne-prone skin care, tone evening and brightening, texture improvement, baby care, sensitive skin solutions, post-procedure recovery and stretch mark care
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
Standalone profit from operations for Q4-2024 were Rs. 108 crore
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
Subscribe To Our Newsletter & Stay Updated